Active Ingredient: Ibrutinib
Ibrutinib as a single agent or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).
Ibrutinib as a single agent or in combination with bendamustine and rituximab (BR) is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.
For this indication, competent medicine agencies globally authorize below treatments:
Oral
420 - 420 mg
From 420 To 420 mg once every day
The recommended dose for the treatment of CLL, either as a single agent or in combination, is 420 mg once daily.
Treatment should continue until disease progression or no longer tolerated by the patient.
When administering ibrutinib in combination with anti-CD20 therapies, it is recommended to administer ibrutinib prior to rituximab or obinutuzumab when given on the same day.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
